Omni Bridgeway Limited (ASX:OBL) Reports Record FY25 Investment Performance
Omni Bridgeway (ASX:OBL) reports record FY25 proceeds, completes Fund 9 transaction, and appoints new Head of Capital Formation.
Omni Bridgeway (ASX:OBL) reports record FY25 proceeds, completes Fund 9 transaction, and appoints new Head of Capital Formation.
MedAdvisor Limited (ASX:MDR) reports a significant decrease in 3Q FY25 revenue, announces cost-cutting measures and strategic initiatives.
betr Entertainment Limited (ASX:BBT) raises A$130 million to fund the acquisition of PointsBet, targeting over A$40 million in annual cost synergies.
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
4DMedical Limited (ASX:4DX) achieves 103% YTD revenue growth and secures key strategic partnerships in Q3 FY2025.
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.
Health and Plant Protein Group Limited (ASX:HPP) releases FY25 Q3 report, highlighting cash flow and ongoing IRS repayment efforts.
BrainChip Holdings Ltd (ASX:BRN) releases Q1 2025 report, highlighting key partnerships and a solid financial position.
G8 Education Limited (ASX:GEM) reports a 14.8% EBIT increase and highlights strategic initiatives during its 2025 AGM.
Donaco International (ASX:DNA) announces Q3 FY2025 results and a share acquisition Scheme Implementation Deed to strengthen its cash position.